364 related articles for article (PubMed ID: 16417570)
1. Modifications of the iron-neuromelanin system in Parkinson's disease.
Fasano M; Bergamasco B; Lopiano L
J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
[TBL] [Abstract][Full Text] [Related]
2. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
3. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
[TBL] [Abstract][Full Text] [Related]
4. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.
Fedorow H; Tribl F; Halliday G; Gerlach M; Riederer P; Double KL
Prog Neurobiol; 2005 Feb; 75(2):109-24. PubMed ID: 15784302
[TBL] [Abstract][Full Text] [Related]
5. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
[TBL] [Abstract][Full Text] [Related]
6. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
[TBL] [Abstract][Full Text] [Related]
7. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.
Fahn S; Cohen G
Ann Neurol; 1992 Dec; 32(6):804-12. PubMed ID: 1471873
[TBL] [Abstract][Full Text] [Related]
8. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
Hirsch E; Graybiel AM; Agid YA
Nature; 1988 Jul; 334(6180):345-8. PubMed ID: 2899295
[TBL] [Abstract][Full Text] [Related]
9. Neuromelanin and Parkinson's disease.
Marsden CD
J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
[TBL] [Abstract][Full Text] [Related]
10. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
Floor E
Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
[TBL] [Abstract][Full Text] [Related]
11. Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrain.
Andringa G; Bol JG; Wang X; Boekel A; Bennett MC; Chase TN; Drukarch B
Neuropathol Appl Neurobiol; 2006 Apr; 32(2):157-69. PubMed ID: 16599944
[TBL] [Abstract][Full Text] [Related]
12. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
Knörle R
Neurotox Res; 2018 Feb; 33(2):515-522. PubMed ID: 28879408
[TBL] [Abstract][Full Text] [Related]
13. A critical review of the function of neuromelanin and an attempt to provide a unified theory.
Nicolaus BJ
Med Hypotheses; 2005; 65(4):791-6. PubMed ID: 15949901
[TBL] [Abstract][Full Text] [Related]
14. The relevance of iron in the pathogenesis of Parkinson's disease.
Sian-Hülsmann J; Mandel S; Youdim MB; Riederer P
J Neurochem; 2011 Sep; 118(6):939-57. PubMed ID: 21138437
[TBL] [Abstract][Full Text] [Related]
15. Protective and toxic roles of dopamine in Parkinson's disease.
Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
[TBL] [Abstract][Full Text] [Related]
16. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
[TBL] [Abstract][Full Text] [Related]
17. Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease.
Gerlach M; Riederer P; Double KL
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S185-8. PubMed ID: 18585086
[TBL] [Abstract][Full Text] [Related]
18. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
[TBL] [Abstract][Full Text] [Related]
20. Neuronal vulnerability in Parkinson's disease.
Double KL
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
